APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma.
about
Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer TherapyA novel intraperitoneal metastatic xenograft mouse model for survival outcome assessment of esophageal adenocarcinomaIcariin displays anticancer activity against human esophageal cancer cells via regulating endoplasmic reticulum stress-mediated apoptotic signaling.Serum microRNA expression signatures as novel noninvasive biomarkers for prediction and prognosis of muscle-invasive bladder cancer.The high expression instead of mutation of p53 is predictive of overall survival in patients with esophageal squamous-cell carcinoma: a meta-analysis.Novel metastatic models of esophageal adenocarcinoma derived from FLO-1 cells highlight the importance of E-cadherin in cancer metastasis.Inhibiting the system xC-/glutathione axis selectively targets cancers with mutant-p53 accumulationThe prognostic value of TP53 mutations in oesophageal adenocarcinoma: a systematic review and meta-analysis.Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance.Inhibiting system xC- and glutathione biosynthesis - a potential Achilles' heel in mutant-p53 cancers.Pattern of p53 protein expression is predictive for survival in chemoradiotherapy-naive esophageal adenocarcinoma.PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies.Mutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma.Potential therapeutic targets of TP53 gene in the context of its classically canonical functions and its latest non-canonical functions in human cancer.p53-Autophagy-Metastasis Link.p53 and metabolism: from mechanism to therapeutics.RETRACTED: Ablation of MCM10 using CRISPR/Cas9 restrains the growth and migration of esophageal squamous cell carcinoma cells through inhibition of Akt signaling.
P2860
Q26766341-9D55D373-6CBC-45A4-9BE3-1D5FB21F7148Q36287407-65EB3312-DAEA-4A03-838F-0363740727BEQ36595883-BD35D7C2-0EFB-49FD-91EB-7768166B8D0EQ37392819-1E476FEF-C3FE-460E-A252-AA9E01F4A124Q37609474-D3B974AC-1061-41F6-AEE8-2D82347E3B70Q37696316-2A589E7A-3DAF-40F3-9C4E-2B36992DE19CQ37736385-EB6BB083-68DB-441E-A265-88C504C94932Q38687715-D2ABEDE0-6FF0-499D-A3A7-F3E33E18B479Q38746991-B21DD7E9-1924-493E-99DA-77EA9844E1FDQ38748208-594DC37E-3719-48E7-921E-514067BD2102Q46277999-4B8709DA-4191-4BE8-899E-F353FFDACD67Q47154860-335E0CEB-DBB3-4486-ABA3-27A4BBE70215Q47274927-C1BCD2E4-D369-494B-AF92-BEF5956AC2B6Q49788157-1D763F8E-E1B2-42F7-9BF1-8DAAC316B262Q52584348-B2F8417B-6229-4D30-B247-44F6ACEF9C06Q54941377-DF99C6F9-AAB9-4EA2-8806-15AF04889146Q55002919-A6EA5A95-CCA7-47CD-870B-D986B6D2F8FAQ55259035-D8184E82-6817-4C80-911D-9534E1E76453
P2860
APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
APR-246 potently inhibits tumo ...... of oesophageal adenocarcinoma.
@en
type
label
APR-246 potently inhibits tumo ...... of oesophageal adenocarcinoma.
@en
prefLabel
APR-246 potently inhibits tumo ...... of oesophageal adenocarcinoma.
@en
P2093
P2860
P50
P1433
P1476
APR-246 potently inhibits tumo ...... of oesophageal adenocarcinoma.
@en
P2093
Christina M Fennell
Cuong P Duong
David S H Liu
Karen G Montgomery
Matthew Read
Walid J Azar
P2860
P304
P356
10.1136/GUTJNL-2015-309770
P407
P577
2015-07-17T00:00:00Z